<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37650236</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>228</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Long COVID After Bamlanivimab Treatment.</ArticleTitle><Pagination><StartPage>S126</StartPage><EndPage>S135</EndPage><MedlinePgn>S126-S135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiad286</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.</AbstractText><AbstractText Label="METHODS">Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.</AbstractText><AbstractText Label="RESULTS">Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.</AbstractText><AbstractText Label="CONCLUSIONS">Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION">NCT04518410.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evering</LastName><ForeName>Teresa H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Carlee B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jilg</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9154-2769</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Eunice</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanusi</LastName><ForeName>Busola</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wohl</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daar</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jonathan Z</ForeName><Initials>JZ</Initials><Identifier Source="ORCID">0000-0001-9914-9662</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klekotka</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Javan</LastName><ForeName>Arzhang Cyrus</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>National Institutes of Health, Rockville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eron</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Currier</LastName><ForeName>Judith S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Davey M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Kara W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ACTIV-2/A5401 Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04518410</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UM1 AI069423</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI069424</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI069432</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068634</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI106701</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069424</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI068634</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 AI068636</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI068636</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>45I6OFJ8QH</RegistryNumber><NameOfSubstance UI="C000711749">bamlanivimab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bamlanivimab</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute sequelae of SARS-CoV-2 infection (PASC)</Keyword><Keyword MajorTopicYN="N">symptom</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. T. H. E. serves as a consultant for Tonix Pharmaceuticals. N. J. received salary support to the institution from Sagent Pharmaceuticals. D. A. W. has received funding to his institution to support research and honoraria for advisory boards and consulting from Gilead Sciences. E. S. D. receives consulting fees from Gilead Sciences, Merck, and GSK/ViiV and research support through his institution from Gilead Sciences and GSK/ViiV. J. Z. L. has received research funding from Merck. P. K. is an employee and shareholder of Eli Lilly. J.J.E. is an ad hoc consultant to GSK/VIR, data monitoring committee chair for Adagio Phase 3 studies. J. S. C. has consulted for Merck and Company. D. M. S. has consulted for Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health, and Brio Clinical. K. W. C. received research funding to institution from Merck Sharp &amp; Dohme and is a consultant for Pardes Biosciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Hosey</LastName><ForeName>Lara</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roa</LastName><ForeName>Jhoanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Nilam</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coombs</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greninger</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Degli-Angeli</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goecker</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daza</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harb</LastName><ForeName>Socorro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dragavon</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aldrovandi</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murtaugh</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutzman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knowles</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erhardt</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waring</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hessinger</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kallianpur</LastName><ForeName>Asha R</ForeName><Initials>AR</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37650236</ArticleId><ArticleId IdType="pmc">PMC10686694</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiad286</ArticleId><ArticleId IdType="pii">7256351</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff &#xa0;D, Sun &#xa0;A, Ssentongo &#xa0;AE, et al. &#xa0;Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open &#xa0;2021; 4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer &#xa0;RR, Rock &#xa0;MA, Vasilevsky &#xa0;N, et al. &#xa0;Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine &#xa0;2021; 74:103722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope &#xa0;AA, Evering &#xa0;TH. Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Infect Dis Clin North Am &#xa0;2022; 36:379&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843334</ArticleId><ArticleId IdType="pubmed">35636906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai &#xa0;F, Tomasoni &#xa0;D, Falcinella &#xa0;C, et al. &#xa0;Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect &#xa0;2022; 28:611.e9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre &#xa0;CH, Murray &#xa0;B, Varsavsky &#xa0;T, et al. &#xa0;Attributes and predictors of long COVID. Nat Med &#xa0;2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminian &#xa0;A, Bena &#xa0;J, Pantalone &#xa0;KM, Burguera &#xa0;B. Association of obesity with postacute sequelae of COVID-19. Diabetes Obes Metab &#xa0;2021; 23:2183&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239834</ArticleId><ArticleId IdType="pubmed">34060194</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Bowe &#xa0;B, Al-Aly &#xa0;Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun &#xa0;2021; 12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>
US Food and Drug Administration . FDA authorizes monoclonal antibodies for treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0. Accessed 5 August 2022.</Citation></Reference><Reference><Citation>
Eli Lilly and Company . Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. &#xa0;2021. https://investor.lilly.com/news-releases/news-release-details/lilly-requests-revocation-emergency-use-authorization. Accessed 5 August 2022.</Citation></Reference><Reference><Citation>

Hodcroft &#xa0;E. CoVariants version 0.1.0. Enabled by data from GISAID. 2020&#x2013;2023. https://covariants.org/per-country?region=United+States. Accessed 5 August 2022.</Citation></Reference><Reference><Citation>Chen &#xa0;P, Nirula &#xa0;A, Heller &#xa0;B, et al. &#xa0;SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med &#xa0;2021; 384:229&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew &#xa0;KW, Moser &#xa0;C, Daar &#xa0;ES, et al. &#xa0;Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun &#xa0;2022; 13:4931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395368</ArticleId><ArticleId IdType="pubmed">35995785</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis &#xa0;HE, Assaf &#xa0;GS, McCorkell &#xa0;L, et al. &#xa0;Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine &#xa0;2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou &#xa0;G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol &#xa0;2004; 159:702&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033648</ArticleId></ArticleIdList></Reference><Reference><Citation>Margalit &#xa0;I, Yelin &#xa0;D, Sagi &#xa0;M, et al. &#xa0;Risk factors and multidimensional assessment of long COVID fatigue: a nested case-control study. Clin Infect Dis &#xa0;2022; 75:1688&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383780</ArticleId><ArticleId IdType="pubmed">35403679</ArticleId></ArticleIdList></Reference><Reference><Citation>Verveen &#xa0;A, Wynberg &#xa0;E, van Willigen &#xa0;HDG, et al. &#xa0;Severe fatigue in the first year following SARS-CoV-2 infection: a prospective cohort study. Open Forum Infect Dis &#xa0;2022; 9:ofac127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995073</ArticleId><ArticleId IdType="pubmed">35415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside &#xa0;DM, Basso &#xa0;MR, Naini &#xa0;SM, et al. &#xa0;Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 1: cognitive functioning. Clin Neuropsychol &#xa0;2022; 36:806&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130818</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolen &#xa0;LT, Mukerji &#xa0;SS, Mejia &#xa0;NI. Post-acute neurological consequences of COVID-19: an unequal burden. Nat Med &#xa0;2022; 28:20&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35039657</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein &#xa0;SL, Flanagan &#xa0;KL. Sex differences in immune responses. Nat Rev Immunol &#xa0;2016; 16:626&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg &#xa0;B, Mohn &#xa0;KG, Brokstad &#xa0;KA, et al. &#xa0;Long COVID in a prospective cohort of home-isolated patients. Nat Med &#xa0;2021; 27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue &#xa0;JK, Franko &#xa0;NM, McCulloch &#xa0;DJ, et al. &#xa0;Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open &#xa0;2021; 4:e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Choi &#xa0;T, Al-Aly &#xa0;Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med &#xa0;2023; 183:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante &#xa0;CT, Buse &#xa0;JB, Liebovitz &#xa0;DM, et al. &#xa0;Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial [manuscript published online ahead of print 8 June 2023]. Lancet Infect Dis &#xa0;2023. doi:10.1016/S1473-3099(23)00299-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi &#xa0;A, Bernabei &#xa0;R, Landi &#xa0;F; Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA &#xa0;2020; 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed &#xa0;MS, Moulin &#xa0;TC, Schioth &#xa0;HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine &#xa0;2021; 71:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657570</ArticleId><ArticleId IdType="pubmed">33179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng &#xa0;F, Dai &#xa0;C, Cai &#xa0;P, et al. &#xa0;A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol &#xa0;2020; 92:2050&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267228</ArticleId><ArticleId IdType="pubmed">32383183</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung &#xa0;JM, Yang &#xa0;CX, Tam &#xa0;A, et al. &#xa0;ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J &#xa0;2020; 55:2000688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144263</ArticleId><ArticleId IdType="pubmed">32269089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell &#xa0;ML, Catalfamo &#xa0;CJ, Farland &#xa0;LV, et al. &#xa0;Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS One &#xa0;2021; 16:e0254347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo &#xa0;SM, Liu &#xa0;TC, Motwani &#xa0;Y, et al. &#xa0;Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med &#xa0;2022; 37:1988&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick &#xa0;JL, Titus &#xa0;AR, Slocum &#xa0;E, et al. &#xa0;Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis &#xa0;2021; 73:2055&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrasik &#xa0;MP, Maunakea &#xa0;AK, Oseso &#xa0;L, et al. &#xa0;Awakening: the unveiling of historically unaddressed social inequities during the COVID-19 pandemic in the United States. Infect Dis Clin North Am &#xa0;2022; 36:295&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8806123</ArticleId><ArticleId IdType="pubmed">35636901</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin &#xa0;P, Casari &#xa0;G, Townsend &#xa0;L, et al. &#xa0;Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med &#xa0;2022; 28:879&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler &#xa0;C, Wang &#xa0;Z, Lorenzi &#xa0;JCC, et al. &#xa0;Evolution of antibody immunity to SARS-CoV-2. Nat Med &#xa0;2021; 591:639&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina &#xa0;F, Catalan &#xa0;P, Rodriguez-Grande &#xa0;C, et al. &#xa0;Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis &#xa0;2022; 22:211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryce &#xa0;C, Grimes &#xa0;Z, Pujadas &#xa0;E, et al. &#xa0;Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol &#xa0;2021; 34:1456&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015313</ArticleId><ArticleId IdType="pubmed">33795830</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli &#xa0;M, Pujol &#xa0;JC, Spector &#xa0;TD, Ourselin &#xa0;S, Steves &#xa0;CJ. Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet &#xa0;2022; 399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>

Goldstein &#xa0;A, Keating &#xa0;D. Long-covid symptoms are less common now than earlier in the pandemic. 2023. https://www.washingtonpost.com/health/2023/03/18/long-covid-less-likely/. Accessed 25 June 2023.</Citation></Reference><Reference><Citation>Watanabe &#xa0;A, Iwagami &#xa0;M, Yasuhara &#xa0;J, Takagi &#xa0;H, Kuno &#xa0;T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine &#xa0;2023; 41:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini &#xa0;E, Levi &#xa0;R, Sarti &#xa0;R, et al. &#xa0;Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA &#xa0;2022; 328:676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>